Please login to the form below

Not currently logged in
Email:
Password:

Almirall/ Nycomed COPD co-branding deal

Almirall and Nycomed have entered into a co-branding agreement for the commercialisation of roflumilast, a once-daily tablet for patients with chronic obstructive pulmonary disease, in Spain

Almirall and Nycomed have entered into a co-branding agreement for the commercialisation of roflumilast, the once-daily tablet for patients with chronic obstructive pulmonary disease (COPD), in Spain.

Roflumilast is an orally administered phosphodiesterase 4 (PDE4) enzyme inhibitor, and the first oral anti-inflammatory treatment for COPD.

Nycomed will receive an undisclosed upfront fee from Almirall, who will be exclusively promoting a second brand of roflumilast in Spain.

Luciano Conde, Almirall's chief operating officer, said: "This product, an entirely new class of treatment, has a strong strategic fit in our business and is fully complementary with other bronchodilator treatments in COPD such as our R&D product aclidinium bromide which is expected to be filed this year.

"We expect roflumilast to generate sales as of this year and could become one of Almirall's key products in the mid-term," he added.

5th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...
Emotional Intelligence and Blended Learning in Healthcare
...

Infographics